CLEOCIN PHOSPHATE (clindamycin phosphate)
CLEOCIN PHOSPHATE is indicated for the treatment of Anaerobic Bacterial Infections; Streptococcal Infections; Pneumococcal Infections; Staphylococcal Infections; Lower Respiratory Tract Infections; Pneumonia; Empyema; Lung Abscess; Skin and Skin Structure Infections; Gynecological Infections.
How CLEOCIN PHOSPHATE Works
Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome. This action interferes with the assembly of the ribosome and the translation process. Clindamycin is typically classified as bacteriostatic.
Details
- Status
- Prescription
- First Approved
- 1972-10-02
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
CLEOCIN PHOSPHATE Approval History
What CLEOCIN PHOSPHATE Treats
10 indicationsCLEOCIN PHOSPHATE is approved for 10 conditions since its original approval in 1972. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Anaerobic Bacterial Infections
- Streptococcal Infections
- Pneumococcal Infections
- Staphylococcal Infections
- Lower Respiratory Tract Infections
- Pneumonia
- Empyema
- Lung Abscess
CLEOCIN PHOSPHATE Boxed Warning
WARNING Clostridioides difficile- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . Because CLEOCIN PHOSPHATE therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial...
WARNING Clostridioides difficile- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . Because CLEOCIN PHOSPHATE therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated.
CLEOCIN PHOSPHATE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to CLEOCIN PHOSPHATE
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT04469075 | 19-342 | Ph 2 | active not recruiting | Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields |
| NCT04321070 | CLPL 1907 | Ph 1 | completed | Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris |
| NCT00616330 | CBC-302-602-622467 | Ph 3 | completed | Vaginal Infection Study |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CLEOCIN PHOSPHATE FDA Label Details
Indications & Usage
FDA Label (PDF)CLEOCIN PHOSPHATE is indicated for the treatment of Anaerobic Bacterial Infections; Streptococcal Infections; Pneumococcal Infections; Staphylococcal Infections; Lower Respiratory Tract Infections; Pneumonia; Empyema; Lung Abscess; Skin and Skin Structure Infections; Gynecological Infections.
WARNING Clostridioides difficile- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to o...
Track CLEOCIN PHOSPHATE with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.